Kiniksa Pharmaceuticals, Ltd. - (KNSA) News
Filter KNSA News Items
KNSA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KNSA News Highlights
- For KNSA, its 30 day story count is now at 4.
- Over the past 2 days, the trend for KNSA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest KNSA News From Around the Web
Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.
Kiniksa Pharmaceuticals First Quarter 2023 Earnings: Beats ExpectationsKiniksa Pharmaceuticals ( NASDAQ:KNSA ) First Quarter 2023 Results Key Financial Results Revenue: US$48.3m (up 50% from... |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue EstimatesKiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution– ARCALYST® (rilonacept) Q1 2023 net product revenue of $42.7 million –– ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint –– Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling patients; data expected in 1H 2024 – – Cash reserves now expected to fund operations into at least 2026 – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, May 02, 2023 (GLOBE |
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a.m. Eastern Time to report its first quarter 2023 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here |
Could The Market Be Wrong About Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Its Attractive Financial Prospects?Kiniksa Pharmaceuticals (NASDAQ:KNSA) has had a rough three months with its share price down 26%. However, a closer... |
7 Thrilling Biotech Stocks for Aggressive Investors to BuyAmid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. |
After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA)Kiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
7 Small-Cap Stocks to Buy for Explosive Growth PotentialAlthough small-cap stocks to buy presents higher risks than the large caps, the segment also enjoys critical advantages. |
12 Cheap Healthcare Stocks to Buy in 2023In this piece, we will take a look at the twelve cheap healthcare stocks to buy in 2023. For more healthcare stocks, head on over to 5 Cheap Healthcare Stocks to Buy in 2023. The healthcare sector is one of the few industries that has rapidly transformed itself in just a couple of decades. Modern […] |
HCA Healthcare (HCA) Expands in Kansas With a Medical PlazaHCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care. |